REG - Renalytix PLC - Directorate Change

RenalytixAnnouncement

02/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241202:nRSB3698Oa&default-theme=true

RNS Number : 3698O  Renalytix PLC  02 December 2024

Renalytix plc

("Renalytix" or the "Company")

 

Directorate Change

Robert Naylor appointed as Non-Executive Director

 

LONDON and NEW YORK, 2 December 2024 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), an artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to drive improved
patient outcomes and advance value-based care, announces the appointment of
Robert Naylor as Non-Executive Director with immediate effect.

 

Robert has 29 years' experience in capital markets, specialising in both the
life sciences and investment companies sectors. Robert is currently CEO and
Co-Founder of Intuitive Investments Group plc, a London Stock Exchange
Specialist Funds Segment investment company providing investors with exposure
to fast growing technology and life sciences businesses. Robert is also
Non-Executive Director of NIOX Group PLC, a company dedicated to improving
asthma diagnosis and management, and PRS REIT plc, a FTSE 250 closed-ended
real estate investment company which invests in high-quality, new build,
family homes in the private rented sector.

 

Previously, Robert was Chairman of Hipgnosis Songs Fund Limited, a FTSE 250
company, which was subject to a recommended cash offer by a newly-formed
company indirectly wholly-owned by investment funds advised by affiliates of
Blackstone Inc. Robert was Chairman of Round Hill Music Royalty Fund Limited
and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC,
trading as Concord. Earlier in his career Robert held various positions within
JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos
Securities plc. Robert is a qualified chartered accountant, having started his
career with Ernst & Young in 1996.

James McCullough, CEO of Renalytix plc, commented: "It is a pleasure to have
Robert join the Board of Renalytix, bringing with him a wealth of knowledge in
the life sciences sector. Robert's capital markets experience and insight is
invaluable to us as an AIM listed business.

 

"Renalytix offers investors unique access to a world-leading kidney prognostic
test, KidneyintelX.dkd: the only test to be FDA approved, granted full
Medicare reimbursement at $950 per test; available to approximately 14 million
US diabetic kidney disease patients; and able to address the needs of
approximately 260 million diabetic kidney disease patients globally."

 

Additional Disclosures Required under the AIM Rules for Companies

Robert Graham Naylor (aged 50) has held the following directorship or
partnerships in the past five years:

 

 Current directorships/partnerships  Previous directorships/partnerships (last five years)
 Intuitive Investments Group PLC     Hipgnosis Songs Fund Limited
 IIG Assets LTD                      Hipgnosis Holdings UK Limited
 The PRS REIT PLC                    Hipgnosis SFH I Limited
 NIOX Group PLC                      Hipgnosis SFH XIX Limited
                                     Hipgnosis SFH XIII Limited
                                     Hipgnosis SFH XX Limited
                                     Deamon Limited
                                     Kennedy Publishing & Productions Limited
                                     PB Songs LTD
                                     RubyRuby (London) Limited
                                     Round Hill Music Royalty Fund Limited

                                     Concord Copyrights No.1 Limited (formerly RHMRF1 Limited)

                                     RHMRF3 Limited

                                     RHMRF2 Limited
                                     Light Science Technologies Holdings PLC
                                     LSTH Trustee Limited

 

Robert Naylor and persons closely associated (as defined under MAR) with Mr
Naylor currently hold 588,055 ordinary shares of £0.0025 each in the Company.

 

Save as disclosed above, there is no further information to be disclosed in
respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph
(g) of the AIM Rules for Companies.

 

For further information, please contact:

 

 Renalytix plc                                www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                        Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)  Tel: 020 7710 7600
 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                Tel: 020 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                          Tel: 020 7933 8780 or renalytix@walbrookpr.com
                                              (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings                Mob: 07980 541 893 / 07407 804 654

 CapComm Partners
 Peter DeNardo                                Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 

About Renalytix

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUAOKRSWUURAA